Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC (ESMO 2026) - Sep 22, 2026 - Abstract #LBA5; Pres time: Oct 25, 2026; 04:30 PM - 04:42 PM; Location: Alicante Auditorium - Hall 6; No abstract available
Clinical • Late-breaking abstract • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS
|
|
Ferdinandos Skoulidis 1; Myung-Ju Ahn 2; Shirish Gadgeel 3; Sanjay Popat 4; Niels Reinmuth 5; Bianca Van Veggel 6; Farastuk Bozorgmehr 7; Victoria J. Bray 8; Michael Duruisseaux 9; Wade T. Iams 10; Julien Mazieres 11; Laura Bonanno 12; Lore Decoster 13; Bo Wang 14; Youyou Hu 15; Sarah M. Shagan 16; Verena Lam 16; Uyi Osaghae 16; Tien Hoang 16; Ben J. Solomon 17
|